Canada markets closed

BeiGene, Ltd. (BGNE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
166.95+5.10 (+3.15%)
At close: 04:00PM EDT
166.90 -0.05 (-0.03%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close161.85
Open159.82
Bid154.41 x 800
Ask180.00 x 800
Day's Range158.48 - 169.04
52 Week Range118.18 - 426.56
Volume225,093
Avg. Volume283,461
Market Cap17.386B
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma

    CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, June 30, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced new data from RATIONALE 306, a global Phase 3 trial evaluating tislelizumab plus chemotherapy in adult patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) without prior syst

  • Business Wire

    BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab

    CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING, June 21, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental biologics license application (sBLA) for the company’s anti-PD-1 inh

  • Business Wire

    BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets

    CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, June 13, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide today announced that its BTK inhibitor BRUKINSA™ (zanubrutinib) has been approved by the Ministry of Health in Kuwait, the National Health Regulatory Authority in Bahrain and the Ministry of Public Health in Qatar for